Fig. 3From: Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaHealthcare resource utilization for PP1M and OAA IPT-weighted cohorts during the 12-month follow-up. CIÂ =Â confidence interval; IPTÂ =Â inverse probability of treatment; OAAÂ =Â oral atypical antipsychotics; PP1MÂ =Â once-monthly paliperidone palmitate; MMCDÂ =Â mean monthly cost difference. * indicates p-value <0.05. 1All Poisson models included a binary indicator for the treatment received at the index date. 2Based on bootstrap results (BÂ =Â 499)Back to article page